Phase II trial of motexafin gadolinium (MGd) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Motexafin gadolinium (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 18 Dec 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2005 New trial record.